multiepitope vaccine against Taenia solium

A multiepitope vaccine against *Taenia solium* is an immunotherapeutic or prophylactic vaccine candidate designed to protect against infections caused by the *Taenia solium* parasite, the causative agent of neurocysticercosis (NCC) and taeniasis. Developed primarily through immunoinformatics, reverse vaccinology, and proteomics, these vaccines are constructed by identifying and joining highly antigenic, non-toxic, and non-allergic B-cell and T-cell epitopes from *T. solium* proteins using flexible linkers. Prominent research from institutions like the Indian Institute of Technology Mandi (IIT Mandi) has focused on designing chimeric multiepitope vaccines that target conserved parasite proteins or cyst fluid antigens. These constructs are designed to interact stably with host immune receptors, such as Toll-like receptor 4 (TLR4), to effectively stimulate both humoral and cellular immune responses, offering a potential strategy to prevent helminthic neglected tropical diseases.

Other names

multi-epitope chimeric vaccine against Taenia soliummulti-epitope vaccine against Taenia soliummultiepitope Taenia solium vaccine